Abstract: Otic compositions are disclosed. The compositions contain an otic drug and a carrier comprising a low molecular weight compound. The compositions do not drain out of the ear after administration.
Abstract: A bioresorbable composite of a non-crystalline calcium phosphate ceramic synthesized within an encapsulating microspheres of bioresorbable polymeric material for use in bone repair and replacement is provided. Also provides are methods for producing these composites as well as porous, 3-dimensional scaffold produced by sintering together microspheres of this bioresorbable composite.
Type:
Grant
Filed:
March 14, 2002
Date of Patent:
June 1, 2010
Assignee:
Drexel University
Inventors:
Cato T. Laurencin, Archel M. A. Ambrosio, Janmeet S. Sahota
Abstract: A safe additive that increases the feeling effects from a hair cosmetic is provided at low costs. The additive that increases the feeling effects has less stickiness, can be easily and uniformly mixed with hair cosmetics, and can provide feelings, effects and advantages that are similar to those of sterol wax and lanolins including lanolin itself, liquid lanolin, and hard lanolin. The additive that increases the feeling effects contains a composition (I) prepared by distillation, fatty acid esterification, decoloring, and deodorization of a by-product obtained when tocopherol is extracted, separated and purified from a vegetable oil deodorized distillate.
Abstract: Disclosed is a solid or semi-solid gelatin nanoparticulate active agent dosage form comprising at least one nanoparticulate active agent and at least one gel forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gelatin form. The active agent particles have an effective average diameter prior to inclusion in the dosage form of less than about 2000 nm. The dosage form of the invention has the advantages of easy administration combined with rapid dissolution of the active agent following administration.
Abstract: Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
Abstract: An oral pharmaceutical formulation comprising iota-carrageenan, one or more neutral gelling polymers and a basic pharmaceutically active ingredient; which formulation inhibits the release of the basic pharmaceutically active ingredient from the formulation at acidic pH; a process for the manufacture of said formulation; and the use of said formulation in medicine.
Type:
Grant
Filed:
June 19, 2002
Date of Patent:
April 20, 2010
Assignee:
AstraZeneca AB
Inventors:
Cynthia Gaik-Lim Khoo, Helena Gustafsson
Abstract: A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.
Type:
Grant
Filed:
April 1, 2002
Date of Patent:
April 13, 2010
Assignee:
Pfizer Inc.
Inventors:
Tugrul T. Kararli, Sandeep Nema, Aziz Karim
Abstract: Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH2 are biologically active compounds; each X is independently selected from —CH2COO-(glycolic acid moiety), —CH(CH3)COO-(lactic acid moiety), —CH2CH2OCH2COO-(dioxanone moiety), —CH2CH2CH2CH2CH2COO-(caprolactone moiety), —(CH2)yCOO—, where y is 2-4 or 6-24 and —(CH2CH2O)zCH2COO—, where z is 2-24; each Y is independently selected from —COCH2O-(glycolic ester moiety), —COCH(CH3)O-(lactic ester moiety), —COCH2OCH2CH2O-(dioxanone ester moiety), —COCH2CH2CH2CH2CH2O-(caprolactone ester moiety), —CO(CH2)mO—, where m is 2-4 or 6-24 and —COCH2O(CH2CH2O)n-where n is between 2-24; R? is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
Abstract: A composition of matter comprising a capsule or tablet, sized and designed for oral ingestion by a human, containing the 3R-3?R stercoisorner of zeaxanthin. The 3R-3?R stereoisomer of zeaxanthin constitutes at least about 90 percent of all zeaxanthin, while S-S and S-R stereoisomers constitute less than about 10 percent of all zeaxanthin in the capsule or tablet. The capsule or tablet contains a sufficient quantity of the 3R-3?R stereoisomer of zeaxanthin to cause a detectable increase in zeaxanthin concentration in retinal tissue, or at least about 0.5 milligrams. It can be concentrated into an oily fluid or prepared in a microencapsulated granular formulation. The zeaxanthin can also be added to various types of foods, such as margarine, dairy products, syrup, cookie dough, and meat preparations. When consumed, the zeaxanthin can help treat and prevent eye diseases including macular degeneration, a leading cause of vision loss.
Type:
Grant
Filed:
December 17, 2002
Date of Patent:
April 6, 2010
Assignee:
ZeaVision LLC.
Inventors:
Kevin M. Garnett, Luis H. Guerra-Santos, Dennis L. Gierhart
Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.
Type:
Grant
Filed:
January 29, 2003
Date of Patent:
March 30, 2010
Assignee:
Avexxin AS
Inventors:
Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne Kristen Holmeide, Lars Skattebol
Abstract: Methylated polystyrene having pendant N-halamine and N-halamine precursor groups. Biocidal particles have been prepared by reacting highly crosslinked methylated polystyrene beads as starting materials with various N-halamine precursor compounds. The resulting polymer beads are halogenated with chlorine or bromine. The porous beads will be useful in disinfection applications, as well as for sanitization and controlling noxious odor when mixed with absorbent materials in items such as disposable diapers, infant swimwear, incontinence pads, bandages, sanitary napkins, pantiliners, mattress covers, shoe inserts, sponges, animal litter, carpets, and fabrics.
Abstract: Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient.
Abstract: The present invention relates to a novel pH triggered, targeted controlled release system. The controlled delivery system of the present invention is substantially a free-flowing powder formed of solid hydrophobic nano-spheres comprising pharmaceutical active ingredients that are encapsulated in a pH sensitive micro-spheres. The invention also relates to the processes for preparing the compositions and processes for using same. The controlled release system can be used to target and control the release of pharmaceutical active ingredients onto certain regions of the gastrointestinal tract including the stomach and the small intestine. The invention further pertains to pharmaceutical products comprising the controlled release system of the present invention.
Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
Type:
Grant
Filed:
January 17, 2006
Date of Patent:
February 16, 2010
Assignee:
Nektar Therapeutics
Inventors:
Michael David Bentley, Michael James Roberts, Xiaoming Shen, Lin Cheng
Abstract: There is provided a new thermo-gelling composition made with methylcellulose and citric acid. This composition may also have an effective amount of a treating agent, which may be a medicinal agent, cosmetic agent, moisturizer, adjuvant, nutritional agent, other ingredients and combinations thereof. The composition is useful in delivering moisturizers or pharmaceutically active agents to the user in a controlled release manner through the mucosal tissues in a body cavity, or on body surfaces, or as a subcutaneously injected medicament. The composition may also be used as a replacement for the soft tissues of the body as in, for example, the foot cushion and cartilage repair.
Type:
Grant
Filed:
June 25, 2004
Date of Patent:
February 9, 2010
Assignee:
Kimberly-Clark Worldwide, Inc.
Inventors:
Yanbin Huang, Shu-Ping Yang, Sharon Linda Greene
Abstract: The invention provides a pressure-sensitive adhesive for the skin excellent in pressure-sensitive adhesiveness to the human skin and repeelability therefrom, which does not cause the horny layer to be torn away in peeling and is lowly irritant to the skin; and tapes or sheets made by using the same. The pressure-sensitive adhesive is characterized by comprising (a) 100 parts by weight of a copolymer which is prepared from an olefinic macromonomer and a vinyl monomer and whose molecular weight (in terms of polystyrene and as determined by gel permeation chromatography (GPC)) has a two-peak distribution (with the proviso that when the copolymer is to be post-cured, the distribution is one as determined before the post cure) and (b) 20 to 250 parts by weight of a softener which is compatible with the copolymer and liquid or pasty at room temperature and has a boiling point of 250 or above (with the proviso that when the content of the softener (b) exceeds 80 parts by weight, the copolymer must be post-cured).
Abstract: The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.
Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
Type:
Grant
Filed:
April 3, 2006
Date of Patent:
December 29, 2009
Assignee:
Intezyne Technologies, Inc.
Inventors:
Kurt Breitenkamp, Kevin N. Sill, Habib Skaff, Rebecca Breitenkamp
Abstract: A cross-linkable monomer comprises a fumaric acid functional group having a first end and a second end, a first spacer group affixed to said first end and comprising at least repeating unit, a first terminal group affixed to said first spacer group, a second spacer group affixed to said second end and comprising at least one ethylene glycol repeating unit, and a second terminal group affixed to said second spacer group. A hydrogel formed by cross-linking the present monomer and a method for making the monomer. A method for forming a hydrogel, comprises the steps of a) synthesizing a copolymer of poly(propylene fumarate) (PPF) and poly(ethylene glycol (PEG) so as to produce P(PF-co-EG), b) synthesizing a PEG-tethered fumarate (PEGF), c) coupling agmatine sulfate to the PEGF to produce PEGF modified with agmatine (Agm-PEGF), and d) cross-linking the P(PF-co-EG) from step a) with Agm-PEGF from step c).
Abstract: Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons.